NASDAQ:ALECAlector Stock Price, Forecast & News

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALEC stock has decreased by 39.4% and is now trading at $15.10.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Alector.

Alector Inc (NASDAQ:ALEC) announced its earnings results on Wednesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.10. The company had revenue of $7.17 million for the quarter, compared to analysts' expectations of $10.60 million. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%.
View Alector's earnings history.

8 analysts have issued 12 month price objectives for Alector's shares. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's share price to reach $32.80 in the next year. This suggests a possible upside of 117.2% from the stock's current price.
View analysts' price targets for Alector.

Media headlines about ALEC stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alector earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Alector.

Alector saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,760,000 shares, an increase of 11.6% from the June 15th total of 5,160,000 shares. Based on an average trading volume of 492,100 shares, the short-interest ratio is currently 11.7 days. Currently, 11.1% of the shares of the company are short sold.
View Alector's Current Options Chain.

Some companies that are related to Alector include Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Denali Therapeutics (DNLI), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Immunovant (IMVT), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX) and Mesoblast (MESO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Cisco Systems (CSCO), Harpoon Therapeutics (HARP), Johnson & Johnson (JNJ), Kaleido Biosciences (KLDO) and AT&T (T).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.18%), Alps Advisors Inc. (0.14%), Swiss National Bank (0.12%), Russell Investments Group Ltd. (0.09%), ProShare Advisors LLC (0.02%) and Principal Financial Group Inc. (0.02%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Russell Investments Group Ltd., Principal Financial Group Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney, and Terrance Mcguire.
View insider buying and selling activity for Alector.

ALEC stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank, First Trust Advisors LP, Arizona State Retirement System, Strs Ohio, Public Employees Retirement Association of Colorado, ProShare Advisors LLC, SG Americas Securities LLC, and Ameritas Investment Partners Inc.. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $15.10.

Alector has a market capitalization of $1.19 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

The official website for Alector is www.alector.com.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]